Aptevo says RAINIER trial on track for 2026 completion, Phase 2 dose selection

Aptevo Therapeutics, Inc.

Aptevo Therapeutics, Inc.

APVO

0.00
  • Aptevo Therapeutics reported updated interim results from its ongoing RAINIER study of mipletamig in frontline acute myeloid leukemia, with trial completion and Phase 2 dose selection targeted by end-2026.
  • Results have already been presented in the update, showing broad clinical activity with a high rate of remission in patients treated with mipletamig alongside standard therapy.
  • Safety profile appeared differentiated versus similar immune-oncology approaches, with no cytokine release syndrome reported in frontline patients in the dataset.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202605130805ACCESSWRNAPR_____1166364) on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.